BIOIDENT Wins Illustrious 2007 Wall Street Journal Technology Innovation Awards
Printed Semiconductor-Based Technology Named Co-Winner for Breakthrough Lab-on-a-Chip with Real-Time Results
"We are delighted to win this prestigious award that recognizes our innovative work on the cutting edge of nanotechnology," said Dr. Wasiq Bokhari, CEO for BIOIDENT. "Once again, BIOIDENT is being acknowledged as the pioneer in applying its unique printed optoelectronics to realworld applications. We will continue to leverage our unique technology to develop new solutions to address major industry challenges."
Utilizing the latest breakthroughs in science and nanotechnology, the BIOIDENT PhotonicLab Platform is used to produce the world’s first disposable photonic labonachip solution for nextgeneration mobile analytics applications, such as water and food analysis, chemical and biological agent detection, and pointofcare diagnostics. BIOIDENT employs a process developed by its parent company, Austria's NANOIDENT Technologies AG, for using an inkjet printer to print electronic circuits on a variety of surfaces, such as plastic foil or glass; the technology makes it possible to apply photosensitive semiconductors directly onto a labonachip. The Platform eliminates the need for complex and expensive readout systems and delivers unprecedented mobility and sensitivity based on existing biological and chemical assays.
About The Wall Street Journal Technology Innovation Awards As part of the 2007 award nomination process, The Wall Street Journal screened more than 800 applications, narrowing the field to about 150 entries. A panel of 13 judges picked category winners and runnersup in 12 different entry categories including computing systems, energy, environment, materials and other base technologies, media/broadcasting, medical research, medical devices, network/internet technologies, 2/3 network security, semiconductors, software and transport. Each entrant was required to offer extensive details and explain why the entry merited consideration. Judging criteria included innovativeness, clarity of explanation, whether the innovation was covered by patents and if it had achieved some measure of success. Factors the panel considered included: the innovation should have gone well beyond what already existed and cannot simply represent incremental improvements; it needed to address major challenges for which new solutions would have a wideranging impact in a particular industry; the written application needed to be supported by rigorous data rather than unsubstantiated claims of potential.
BIOIDENT Technologies Inc.n
BIOIDENT is the leader in the development of rapid, multiassay and mobile analytical and diagnostic systems. BIOIDENT integrates highly sensitive printed photodetectors and electronics with various existing Labona-Chip (LOC) technologies including lateral flow, microfluidics and microarrays. BIOIDENT’s systems are designed for applications in invitro diagnostics, chemical and biological threat detection, and environmental testing. BIOIDENT’s awardwinning Photonic Lab™ Technology Platform eliminates the need for complex and expensive readout systems and delivers unprecedented mobility and sensitivity based on existing biological and chemical assays. Benefits for BIOIDENT’s 3/3 customers and partners include high mobility, rapid testing, multiplexing and low cost of ownership.
BIOIDENT is a subsidiary of Austrianbased NANOIDENT Technologies AG, the world leader in printed optoelectronics. The company is privately held with headquarters in Menlo Park, California. BIOIDENT leverages NANOIDENT’s SEMICONDUCTOR 2.0™ Platform technology and its highspeed manufacturing process, which uses liquid conductive and semiconductive materials to print electronic circuits on almost any surface using an inkjet printer. NANOIDENT also has the world’s only dedicated organic fabrication facility with a production output of 40,000 sq.m per year. For more information about the company, please visit www.bioident.com.